屈西多巴
屈西多巴结构式
|
常用名 | 屈西多巴 | 英文名 | droxidopa |
|---|---|---|---|---|
| CAS号 | 23651-95-8 | 分子量 | 213.187 | |
| 密度 | 1.608g/cm3 | 沸点 | 549.8±50.0 °C at 760 mmHg | |
| 分子式 | C9H11NO5 | 熔点 | 232-235° (dec); mp 229-232° (dec) (Ohashi) | |
| MSDS | 中文版 美版 | 闪点 | 286.3±30.1 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.
Eur. J. Pharm. Sci. 64 , 37-43, (2014) The aim of this study was to compare the dissolution profiles of oral disintegrating tablets (ODTs) and immediate release (IR) formulations in order to experimentally validate the regulatory biowaiver scheme (BWS) for biopharmaceutical classification system (... |
|
|
[Acute poisoning of droxidopa: report of a case].
Chudoku. Kenkyu. 26(3) , 244-5, (2013)
|
|
|
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.
Neurobiol. Aging 33(8) , 1651-63, (2012) Damage to noradrenergic neurons in the locus coeruleus (LC) is a hallmark of Alzheimer's disease (AD) and may contribute to disease progression. In 5xFAD transgenic mice, which accumulate amyloid burden at early ages, the LC undergoes stress as evidenced by i... |
|
|
Comment on "Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension" by Fujisaki et al.
Ther. Apher. Dial. 11(5) , 407-8, (2007)
|
|
|
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
Hypertension 65(1) , 101-7, (2015) We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patie... |
|
|
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
Clin. Auton. Res. 18 Suppl 1 , 25-9, (2008) Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a ... |
|
|
L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
Clin. Auton. Res. 18 Suppl 1 , 19-24, (2008) Neurogenic orthostatic hypotension results from failure to release norepinephrine, the neurotransmitter of sympathetic postganglionic neurons, appropriately upon standing. In double blind, cross over, placebo controlled trials, administration of droxidopa, a ... |
|
|
Diastereoselective synthesis of L: -threo-3,4-dihydroxyphenylserine by low-specific L: -threonine aldolase mutants.
Biotechnol. Lett. 32(1) , 143-9, (2010) Diastereoselectivity-enhanced mutants of L: -threonine aldolase (L: -TA) for L: -threo-3,4-dihydroxyphenylserine (L: -threo-DOPS) synthesis were isolated by error-prone PCR followed by a high-throughput screening. The most improved mutant was achieved from th... |
|
|
Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
J. Clin. Pharmacol. 51(1) , 66-74, (2011) L-threo-3,4-dihydroxyphenylserine (L-DOPS), a norepinephrine (NE) prodrug, is investigational for orthostatic hypotension, which occurs commonly in Parkinson's disease. Adjunctive anti-parkinsonian drugs might interact with L-DOPS. We tested whether L-aromati... |
|
|
Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Ther. Apher. Dial. 11(1) , 49-55, (2007) Orthostatic hypotension (OH) after hemodialysis (HD) is a serious complication, as it causes various neurological symptoms and even ischemic brain damage. The aim of the present study was to evaluate the effects of antihypotensive agents, midodrine hydrochlor... |